Last reviewed · How we verify
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]
Beta-3 agonists activate beta-3 adrenergic receptors on the detrusor muscle of the bladder to increase muscle relaxation and increase bladder capacity.
Beta-3 agonists activate beta-3 adrenergic receptors on the detrusor muscle of the bladder to increase muscle relaxation and increase bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency, Neurogenic detrusor overactivity (for vibegron).
At a glance
| Generic name | Beta3-Agonists, Adrenergic [Mirabegron/Vibegron] |
|---|---|
| Sponsor | Women and Infants Hospital of Rhode Island |
| Drug class | Beta-3 adrenergic agonist |
| Target | Beta-3 adrenergic receptor (ADRB3) |
| Modality | Small molecule |
| Therapeutic area | Urology / Neurology |
| Phase | FDA-approved |
Mechanism of action
Beta-3 adrenergic receptors are predominantly expressed in the bladder detrusor smooth muscle. Activation of these receptors triggers a signaling cascade that increases cAMP levels, leading to smooth muscle relaxation and reduced bladder contractions. This allows the bladder to store larger volumes of urine with fewer involuntary contractions, reducing urinary frequency and urgency.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency
- Neurogenic detrusor overactivity (for vibegron)
Common side effects
- Hypertension
- Headache
- Nasopharyngitis
- Urinary tract infection
- Dizziness
- Tachycardia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: